Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

FDA Places Trials of MCL-1 Inhibitor on Clinical Hold

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on a phase I, dose-escalation study of AMG 397, an oral, small...

FDA Awards 12 New Research Grants for Rare Diseases, Including AML

The U.S. Food and Drug Administration (FDA) has awarded 12 new grants totaling more than $1 million for the development of medical devices, drugs,...

Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia

In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...

Clofarabine Plus Cytarabine May Provide Less Toxic Option for Newly Diagnosed Pediatric Patients With...

For children newly diagnosed with acute myeloid leukemia (AML), treatment with a combination of clofarabine plus cytarabine was associated with similar survival rates when...
On location

Guadecitabine Performs No Better Than Other Hypomethylating Agents in Treatment-Naïve Acute Myeloid Leukemia

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) show that this...
WIB_icon

Risk of Severe GVHD Lower With Post-Transplant Cyclophosphamide Than ATG in Mismatched Unrelated Donor...

Antithymocyte globulin (ATG) is considered standard graft-versus-host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) who undergo transplantation with a mismatched unrelated...
On location

Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia

Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to myelosuppression, but according to results from a study presented...
On location

Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia

Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced high response rates in adult patients with Philadelphia chromosome...

Mixed Opinions on Quizartinib From the FDA and Japanese Regulators

After the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee decided against recommending approval of quizartinib for patients with relapsed/refractory FLT3-ITD acute...
On location

Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden

According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...

SHARE